Play it down until it gets more expensive!
Home for the "bears"
As analysts explain, after almost three months of growth, there has not been a serious correction yet. For this reason, investors are starting to get nervous and take profits. Investment companies believe that the decline may continue. At the same time, the indicator may roll back below 1500 points. Meanwhile, domestic pharmaceutical companies traded noticeably better than the market. However, only two turned out to be in the black – "Pharmsintez" and, traditionally, "Protek".
The Russian stock market lost almost all of the growth it received a week earlier and again fell below 1600 points on the MICEX index. The indicator lost 4.34% and ended up at the level of 1554.04 points. For comparison, a decrease of within 1% was observed on the main world markets.
"This situation is due to the fact that after reaching the annual highs, a more or less serious correction did not occur. There is no inflow of fresh "money" to the market. As a result, investors are starting to get nervous, realizing that the external background is not so positive now for the resumption of the rally. Apparently, investors prefer to fix at least part of the "profit" rather than risk and continue to hold shares," says Denis Barabanov, head of the analytical department of IC Grandis Capital.
"The whole question now is who is more on the market now, those who have been actively buying in securities for a month and a half, or those who did not have time to buy. For me, the answer is obvious, the lagging demand is small now, and it cannot be large, given three months of almost unrestrained growth. Therefore, I believe that at the moment there is a reversal in the market and the beginning of the formation of a downward trend," adds Mikhail Fedorov, an analyst at RIK–Finance.
"Apparently, after the falls of the last few days, market participants just need to look around to understand the validity of the current levels either for the resumption of sales or for the next purchases," says Alexander Potavin, head of the analytical department of IC ITinvest – Prospect.
"At the moment, the exchange is the home of the bears, and I do not advise managing on their territory," warns Andrey Vernikov, Deputy General Director for Investment Analysis at Cerih Capital Management IC. – In our market, a gentle downward trend is most likely with a decline to the level of 1,480 points on the MICEX index."
Bulls and bears on the stock exchange
William Holbrook Beard (William Holbrook Beard), 1825 – 1900, American artist
CentenariansShares of domestic pharmaceutical companies traded better than the market.
The worst dynamics was demonstrated by the securities of the Pharmacy Chain 36.6, which sank by 3.03% to 43.14 rubles. Slightly less than the loss of Veropharm, the decline in the share price was 2.7%. As a result, the price stopped at 900 rubles.
Pharmstandard also turned out to be in the red, whose securities fell by 2.85% to 1,753 rubles. On the tape of the Reuters news agency, material was published that in 2010 Stada allegedly negotiated the purchase of Pharmstandard. "Russian entrepreneur, inspirer and the main shareholder of Pharmstandard, Viktor Kharitonin, appealed to the management of Stada with a merger proposal that would allow the German company to gain access to the production sites and personnel of the Russian partner and thus further strengthen its position in the Russian pharmaceutical market," the news agency writes. "In turn, the Russian company would have access to German know–how, which would help bring the production level to Western standards and ease its dependence on the markets of the former USSR countries." In "Pharmstandard", "FV" confirmed that negotiations with Stada were indeed conducted. However, it was not about selling the business of a Russian manufacturer to a German company. Pharmstandard declined to comment further.
BeginnersAnd the "Leak" does not care about the decline of the market.
The company's shares rose by 1.62% to 26.4 rubles. Since the beginning of February, the growth of securities has already amounted to more than 45%. However, last week the leader was not Protek, but Pharmsintez, whose shares rose by 1.9% to 21.4 rubles.
The rest of the newcomers are in the red. Thus, the Institute of Human Stem Cells sank by 1.06%, to 12.66 rubles. Meanwhile, the company announced that it had submitted documents for registration of its Neovasculgen drug for the treatment of lower limb ischemia in Ukraine. In Russia, the medicine received a registration certificate on December 7, 2011. The start of sales in the domestic market is scheduled for the II quarter of this year. "Ukraine is the first foreign market to which the HSC is going to bring the drug. In the future, we plan to promote it on the territory of the European Union and the United States," said Artur Isaev, Director General of the ISKCH. ISKCH has high hopes for Neovasculgen. According to the company's forecasts, if in 2012 the drug will provide 9% of the company's revenue, then in 2016 it will already be 45%.
The outsider among the "recruits" is "Diode". His securities fell by 2.15%, to 15.25 rubles.
Their moresAbbott Laboratories became the leader in stock growth and the main newsmaker among American pharmaceutical companies.
Its securities rose by 2.37% to $60.39. It became known the name of the company in which Abbott plans to allocate its pharmaceutical business – AbbVie. Its portfolio will include drugs with annual sales of $18 billion. The company will also work on the development of medicines for the treatment of hepatitis C, immunological, oncological and neurological diseases, chronic kidney failure, as well as for women's health. Abbott announced plans to split the business into two independent companies in October last year. The second company will specialize in medical products.
Abbott sued Watson Pharmaceuticals for patent infringement on the drug Niaspan, which reduces cholesterol levels in the blood. Abbott demands that Watson stop selling the generic version of the drug. For Abbott, Niaspan is one of the most significant. At the end of 2011, its sales amounted to about $ 1 billion. In addition, Deutsche Bank raised its recommendation on Abbott shares from "hold" to "buy". The target price is $76 per piece. Thus, according to the bank, the growth potential exceeds 25% of the current level.
Portal "Eternal youth" http://vechnayamolodost.ru
26.03.2012